Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis evaluated the efficacy and safety of traditional GLP-1 RAs, DPP-4is, and SGLT-2is compared with insulin. Comprehensive searches were conducted in the Cochrane Database, PubMed, MEDLINE, ClinicalTrials.gov, and EMBASE for publications from January 2010 to June 2022, with an additional search extended through June 2025 to capture newly published studies. Randomized controlled trials (RCTs) comparing insulin with established GLP-1 RAs, DPP-4is, or SGLT-2is were included. Thirteen trials involving 5,807 participants were identified. Nine trials compared GLP-1 RAs to insulin, four compared DPP-4is to insulin, and one examined SGLT-2i combined with DPP-4i versus insulin. Compared with insulin, traditional non-insulin agents were associated with greater reductions in hemoglobin A1c (HbA1c) (mean difference (MD) = -0.27, 95% confidence interval (CI) -0.5 to -0.03), body weight (MD = -3.27, 95% CI -4.16 to -2.38), and systolic blood pressure (MD = -3.55, 95% CI -4.92 to -2.17). Insulin use carried a higher relative risk of hypoglycemia (risk ratio (RR) = 2.24, 95% CI 1.88-2.67). Subgroup analyses showed that GLP-1 RAs were superior to insulin in reducing HbA1c and…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 5,807 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.